102 related articles for article (PubMed ID: 15102940)
1. Molecular determinants for high-affinity block of human EAG potassium channels by antiarrhythmic agents.
Gessner G; Zacharias M; Bechstedt S; Schönherr R; Heinemann SH
Mol Pharmacol; 2004 May; 65(5):1120-9. PubMed ID: 15102940
[TBL] [Abstract][Full Text] [Related]
2. Structural determinants of HERG channel block by clofilium and ibutilide.
Perry M; de Groot MJ; Helliwell R; Leishman D; Tristani-Firouzi M; Sanguinetti MC; Mitcheson J
Mol Pharmacol; 2004 Aug; 66(2):240-9. PubMed ID: 15266014
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241.
Gessner G; Heinemann SH
Br J Pharmacol; 2003 Jan; 138(1):161-71. PubMed ID: 12522086
[TBL] [Abstract][Full Text] [Related]
4. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
5. Molecular determinants of KCNQ1 channel block by a benzodiazepine.
Seebohm G; Chen J; Strutz N; Culberson C; Lerche C; Sanguinetti MC
Mol Pharmacol; 2003 Jul; 64(1):70-7. PubMed ID: 12815162
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human ether à go-go potassium channels by Ca(2+)/calmodulin.
Schönherr R; Löber K; Heinemann SH
EMBO J; 2000 Jul; 19(13):3263-71. PubMed ID: 10880439
[TBL] [Abstract][Full Text] [Related]
7. A structural basis for drug-induced long QT syndrome.
Mitcheson JS; Chen J; Lin M; Culberson C; Sanguinetti MC
Proc Natl Acad Sci U S A; 2000 Oct; 97(22):12329-33. PubMed ID: 11005845
[TBL] [Abstract][Full Text] [Related]
8. High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
Thomas D; Wendt-Nordahl G; Röckl K; Ficker E; Brown AM; Kiehn J
J Pharmacol Exp Ther; 2001 May; 297(2):753-61. PubMed ID: 11303067
[TBL] [Abstract][Full Text] [Related]
9. Molecular determinants of HERG channel block.
Kamiya K; Niwa R; Mitcheson JS; Sanguinetti MC
Mol Pharmacol; 2006 May; 69(5):1709-16. PubMed ID: 16474003
[TBL] [Abstract][Full Text] [Related]
10. A single amino acid difference between ether-a-go-go- related gene channel subtypes determines differential sensitivity to a small molecule activator.
Perry M; Sanguinetti MC
Mol Pharmacol; 2008 Apr; 73(4):1044-51. PubMed ID: 18162604
[TBL] [Abstract][Full Text] [Related]
11. Structural determinants for high-affinity block of hERG potassium channels.
Mitcheson J; Perry M; Stansfeld P; Sanguinetti MC; Witchel H; Hancox J
Novartis Found Symp; 2005; 266():136-50; discussion 150-8. PubMed ID: 16050266
[TBL] [Abstract][Full Text] [Related]
12. Functional distinction of human EAG1 and EAG2 potassium channels.
Schönherr R; Gessner G; Löber K; Heinemann SH
FEBS Lett; 2002 Mar; 514(2-3):204-8. PubMed ID: 11943152
[TBL] [Abstract][Full Text] [Related]
13. In vivo targeting of ERG potassium channels in mice and dogs by a positron-emitting analogue of fluoroclofilium.
Kim SW; Yang SD; Ahn BJ; Park JH; Lee DS; Gessner G; Heinemann SH; Herdering W; Yu KH
Exp Mol Med; 2005 Aug; 37(4):269-75. PubMed ID: 16155403
[TBL] [Abstract][Full Text] [Related]
14. Effects of outer mouth mutations on hERG channel function: a comparison with similar mutations in the Shaker channel.
Fan JS; Jiang M; Dun W; McDonald TV; Tseng GN
Biophys J; 1999 Jun; 76(6):3128-40. PubMed ID: 10354437
[TBL] [Abstract][Full Text] [Related]
15. Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels.
Yang BF; Xu DH; Xu CQ; Li Z; Du ZM; Wang HZ; Dong DL
Acta Pharmacol Sin; 2004 May; 25(5):554-60. PubMed ID: 15132818
[TBL] [Abstract][Full Text] [Related]
16. Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs.
Perry M; Stansfeld PJ; Leaney J; Wood C; de Groot MJ; Leishman D; Sutcliffe MJ; Mitcheson JS
Mol Pharmacol; 2006 Feb; 69(2):509-19. PubMed ID: 16291873
[TBL] [Abstract][Full Text] [Related]
17. Molecular site of action of the antiarrhythmic drug propafenone at the voltage-operated potassium channel Kv2.1.
Madeja M; Leicher T; Friederich P; Punke MA; Haverkamp W; Musshoff U; Breithardt G; Speckmann EJ
Mol Pharmacol; 2003 Mar; 63(3):547-56. PubMed ID: 12606761
[TBL] [Abstract][Full Text] [Related]
18. Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels.
Dong DL; Li Z; Wang HZ; Du ZM; Song WH; Yang BF
Basic Clin Pharmacol Toxicol; 2004 May; 94(5):209-12. PubMed ID: 15125690
[TBL] [Abstract][Full Text] [Related]
19. C-Linker Accounts for Differential Sensitivity of ERG1 and ERG2 K+ Channels to RPR260243-Induced Slow Deactivation.
Gardner A; Sanguinetti MC
Mol Pharmacol; 2015 Jul; 88(1):19-28. PubMed ID: 25888115
[TBL] [Abstract][Full Text] [Related]
20. Molecular identification and characterisation of the human eag2 potassium channel.
Ju M; Wray D
FEBS Lett; 2002 Jul; 524(1-3):204-10. PubMed ID: 12135768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
